Articles published by Immuneering Corporation
![](https://ml.globenewswire.com/media/53f47482-3967-413c-b106-7062bb5140f7/small/immuneering-logo-1-png.png)
Via GlobeNewswire
Tickers
IMRX
![](https://ml.globenewswire.com/media/53f47482-3967-413c-b106-7062bb5140f7/small/immuneering-logo-1-png.png)
Via GlobeNewswire
Tickers
IMRX
![](https://ml.globenewswire.com/media/53f47482-3967-413c-b106-7062bb5140f7/small/immuneering-logo-1-png.png)
![](https://ml.globenewswire.com/media/53f47482-3967-413c-b106-7062bb5140f7/small/immuneering-logo-1-png.png)
Via GlobeNewswire
Tickers
IMRX
![](https://ml.globenewswire.com/media/53f47482-3967-413c-b106-7062bb5140f7/small/immuneering-logo-1-png.png)
Via GlobeNewswire
Tickers
IMRX
![](https://ml.globenewswire.com/media/53f47482-3967-413c-b106-7062bb5140f7/small/immuneering-logo-1-png.png)
![](https://ml.globenewswire.com/media/53f47482-3967-413c-b106-7062bb5140f7/small/immuneering-logo-1-png.png)
![](https://ml.globenewswire.com/media/53f47482-3967-413c-b106-7062bb5140f7/small/immuneering-logo-1-png.png)
Via GlobeNewswire
Tickers
IMRX
![](https://ml.globenewswire.com/media/53f47482-3967-413c-b106-7062bb5140f7/small/immuneering-logo-1-png.png)
Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors
March 11, 2024
Via GlobeNewswire
Tickers
IMRX
![](https://ml.globenewswire.com/media/53f47482-3967-413c-b106-7062bb5140f7/small/immuneering-logo-1-png.png)
![](https://ml.globenewswire.com/media/53f47482-3967-413c-b106-7062bb5140f7/small/immuneering-logo-1-png.png)
Via GlobeNewswire
Tickers
IMRX
![](https://ml.globenewswire.com/media/53f47482-3967-413c-b106-7062bb5140f7/small/immuneering-logo-1-png.png)
![](https://ml.globenewswire.com/media/53f47482-3967-413c-b106-7062bb5140f7/small/immuneering-logo-1-png.png)
Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer
February 20, 2024
Via GlobeNewswire
Tickers
IMRX
![](https://ml.globenewswire.com/media/53f47482-3967-413c-b106-7062bb5140f7/small/immuneering-logo-1-png.png)
Immuneering Announces Participation in February Investor Conferences
February 01, 2024
Via GlobeNewswire
Tickers
IMRX
![](https://ml.globenewswire.com/media/53f47482-3967-413c-b106-7062bb5140f7/small/immuneering-logo-1-png.png)
![](https://ml.globenewswire.com/media/53f47482-3967-413c-b106-7062bb5140f7/small/immuneering-logo-1-png.png)
Via GlobeNewswire
Tickers
IMRX
![](https://ml.globenewswire.com/media/53f47482-3967-413c-b106-7062bb5140f7/small/immuneering-logo-1-png.png)
Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates
November 09, 2023
Via GlobeNewswire
Tickers
IMRX
![](https://ml.globenewswire.com/media/53f47482-3967-413c-b106-7062bb5140f7/small/immuneering-logo-1-png.png)
![](https://ml.globenewswire.com/media/53f47482-3967-413c-b106-7062bb5140f7/small/immuneering-logo-1-png.png)
![](https://ml.globenewswire.com/media/53f47482-3967-413c-b106-7062bb5140f7/small/immuneering-logo-1-png.png)
Immuneering to Present at the Morgan Stanley Healthcare Conference
September 06, 2023
Via GlobeNewswire
Tickers
IMRX
![](https://ml.globenewswire.com/media/53f47482-3967-413c-b106-7062bb5140f7/small/immuneering-logo-1-png.png)
Immuneering Reports Second Quarter 2023 Financial Results and Provides Business Updates
August 03, 2023
Via GlobeNewswire
Tickers
IMRX
![](https://ml.globenewswire.com/media/53f47482-3967-413c-b106-7062bb5140f7/small/immuneering-logo-1-png.png)
![](https://ml.globenewswire.com/media/53f47482-3967-413c-b106-7062bb5140f7/small/immuneering-logo-1-png.png)
Via GlobeNewswire
Tickers
IMRX
![](https://ml.globenewswire.com/media/53f47482-3967-413c-b106-7062bb5140f7/small/immuneering-logo-1-png.png)
Via GlobeNewswire
Tickers
IMRX
![](https://ml.globenewswire.com/media/53f47482-3967-413c-b106-7062bb5140f7/small/immuneering-logo-1-png.png)
Immuneering Announces $30 Million Underwritten Offering
April 18, 2023
Via GlobeNewswire
Tickers
IMRX
![](https://ml.globenewswire.com/media/53f47482-3967-413c-b106-7062bb5140f7/small/immuneering-logo-1-png.png)
![](https://ml.globenewswire.com/media/53f47482-3967-413c-b106-7062bb5140f7/small/immuneering-logo-1-png.png)
Via GlobeNewswire
Tickers
IMRX
![](https://ml.globenewswire.com/media/53f47482-3967-413c-b106-7062bb5140f7/small/immuneering-logo-1-png.png)
![](https://ml.globenewswire.com/media/53f47482-3967-413c-b106-7062bb5140f7/small/immuneering-logo-1-png.png)
Via GlobeNewswire
Tickers
IMRX
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.